Sarcopenia

Sarcopenia is the progressive loss of skeletal muscle mass, strength and function that accompanies aging. It begins quietly in mid-adulthood, accelerates after about sixty, and by late life is the main physical substrate of frailty: the difference between rising from a chair unaided and not, between a stumble recovered and a hip fractured. It is also a test case for geroscience, because it is the age-related condition where the best treatment is unambiguous, cheap, and not a drug — and where the drug pipeline built to supplement it has so far added muscle without adding function.

§From adjective to diagnosis

Muscle wasting in the old was described for as long as medicine has described the old, but it had no name and therefore no research programme. In 1989 the nutritionist Irwin Rosenberg, closing a meeting on nutrition and aging, argued that no decline with age is more dramatic or functionally significant than the loss of lean body mass, and proposed giving it a Greek name — sarcopenia, "poverty of flesh" — precisely so that it would be studied and measured rather than accepted.¹

The gambit worked slowly. The European Working Group on Sarcopenia in Older People (EWGSOP) published the first widely adopted operational definition in 2010, combining low muscle mass with low strength or performance; its 2019 revision, EWGSOP2, inverted the order, making low strength the primary criterion, muscle quantity confirmatory, and poor physical performance a marker of severity.² The reordering reflected a decade of cohort data showing that strength predicts disability and death better than mass does. In 2016 the condition received an ICD-10-CM code, M62.84 — a bureaucratic event the field's journals greeted as a milestone, because a code is what lets a condition be diagnosed, billed, counted, and targeted by a drug label.³

1. 1989
   Term proposed
   Irwin Rosenberg, summarising a meeting on nutrition and aging, proposes 'sarcopenia' for age-related loss of lean mass, arguing that an unnamed phenomenon cannot be studied.
2. 1990
   Nonagenarians respond to training
   Fiatarone and colleagues show that eight weeks of high-intensity resistance training roughly doubles strength in frail nursing-home residents around age ninety.
3. 1997
   Myostatin discovered
   McPherron and Lee identify GDF-8, a negative regulator of muscle growth; knockout mice with doubled muscle mass hand the field its most obvious drug target.
4. 2010
   First EWGSOP consensus
   A European working group publishes the first operational definition, combining low muscle mass with low strength or performance.
5. 2015
   Myostatin antibody tested in weak fallers
   LY2495655 increases appendicular lean mass in adults 75 and older but leaves grip strength unchanged, setting the pattern for the pipeline.
6. 2016
   ICD-10-CM code assigned
   Sarcopenia receives code M62.84, formal recognition as a reportable condition in the United States.
7. 2019
   EWGSOP2 puts strength first
   The revised consensus makes low strength the primary criterion, demoting muscle quantity to confirmation.
8. 2024
   A global conceptual definition
   The Global Leadership Initiative in Sarcopenia publishes a Delphi consensus intended to reconcile the competing regional definitions.

§Mechanisms

Sarcopenia is not one process. The most direct evidence of what happens comes from whole-muscle autopsy cross-sections: the aging atrophy of the vastus lateralis reflects a loss of muscle fibres, not merely shrinkage of surviving ones, beginning around the third decade and affecting fast type II fibres disproportionately.⁴ Behind the fibre loss sits motor neuron loss — aging muscle undergoes cycles of denervation and reinnervation in which surviving motor units grow larger and less precise, which is part of why power declines faster than mass.

Several Hallmarks of aging converge on the tissue. Muscle stem cells (satellite cells) decline in number and regenerative capacity, the muscle-specific case of Stem cell exhaustion. Mitochondrial function falls, and impaired clearance of damaged mitochondria — a failure of Autophagy — is the rationale for one of the few supplements tested in randomised trials. Chronic low-grade inflammation, described under Inflammaging, suppresses muscle protein synthesis, and senescent cells accumulating through Cellular senescence contribute to the signalling. Layered over all of this is anabolic resistance: aged muscle mounts a blunted protein-synthesis response to the same meal or the same bout of exercise that would build muscle in the young, so maintenance requires a stronger stimulus precisely when the stimulus tends to weaken.

Disuse amplifies everything. Bed rest strips muscle from an older adult in days, and the resemblance between sarcopenia and the deconditioning of spaceflight is close enough that countermeasure research crosses between geriatrics and space physiology.

§Scale and consequences

How common sarcopenia is depends almost entirely on whose definition is applied. A 2022 systematic review and meta-analysis put global prevalence between roughly 10% and 27% in people aged sixty and over, with the spread driven more by the choice of diagnostic criteria than by geography.⁵ That instability is not a footnote; it is one of the field's central problems, discussed below.

The consequences are better established than the prevalence. Low grip strength and slow gait speed — the measures at the heart of every definition — predict falls, hospitalisation, loss of independence and death across large cohorts, which is why they serve as endpoints in trials and why muscle is considered the most tractable domain in functional aging measurement and in the XPRIZE Healthspan competition. Sarcopenia also interacts with the era's dominant pharmacology: GLP-1 receptor agonists produce substantial weight loss of which a meaningful fraction is lean tissue, and preserving muscle during pharmacological weight loss has become the commercial question pulling muscle-drug candidates away from sarcopenia itself.

Mass is not function

Every drug that has entered trials for sarcopenia has been judged, implicitly, on the assumption that added muscle means added ability. The trials keep severing that link: lean mass rises on drug after drug while strength and performance do not. Until a molecule moves a functional endpoint, muscle mass remains an unvalidated surrogate — and regulators treat it as one.

§What works

The intervention with unambiguous evidence is progressive resistance exercise, and the evidence reaches further into old age than intuition suggests. In 1990, Fiatarone and colleagues put frail nursing-home residents around age ninety through eight weeks of high-intensity strength training: strength gains averaged 174%, mid-thigh muscle area grew about 9%, and gait speed improved; a larger randomised trial in 1994 confirmed that training, unlike nutritional supplementation alone, improved strength and mobility in the very old.⁶ Nothing in the drug pipeline has approached effects of that size. The broader case for training as the benchmark geroprotective intervention is made at Exercise as a geroprotector.

Nutrition matters at the margins. Anabolic resistance implies older adults need a stronger protein stimulus, and several consensus groups recommend higher intakes in older age, though trial evidence for supplementation is clearest in people who are undernourished and modest in those who are not. The supplement market runs well ahead of that evidence. Conversely, severe Caloric restriction — the best-studied lifespan intervention in animals — costs lean mass, which is a principal reason it translates poorly to the population that already has sarcopenia.

§The drug pipeline

The pipeline's history is a single lesson taught repeatedly. Myostatin, the negative regulator of muscle growth discovered in 1997, made muscle one of the most druggable tissues in the body, and Myostatin inhibition became the field's flagship approach. In a phase 2 trial in weak older adults who had fallen, the antibody LY2495655 increased appendicular lean mass but not grip strength; bimagrumab, an antibody blocking the activin type II receptors, likewise increased lean mass and cut fat mass in older adults with sarcopenia while physical function improved no more than in the control arm, which had received only nutrition advice and light exercise.⁷ Bimagrumab's subsequent path is telling: licensed out of Novartis, acquired with Versanis by Eli Lilly in 2023, it is now developed for preserving lean mass during pharmacological weight loss — a market with a measurable surrogate endpoint — rather than for sarcopenia.

Newer mechanisms have fared no better so far. Azelaprag, an oral apelin-receptor agonist developed by BioAge Labs on the rationale that apelin is an exercise-induced signal that declines with age, had shown prevention of muscle atrophy during bed rest in a small phase 1b study; its phase 2 obesity trial alongside tirzepatide was discontinued in December 2024 after liver-enzyme elevations in the azelaprag arms.⁸ Urolithin A, a gut-microbiome metabolite that stimulates mitophagy, is sold as a supplement and has been tested in randomised trials: in sixty-six sedentary adults aged 65 to 90, four months of supplementation improved a muscle-endurance measure at two months, but six-minute walk distance and other outcomes did not separate from placebo.⁹ As of 2026 no regulator has approved any drug for sarcopenia.

§Open problems

The definition moves under the trials

EWGSOP, EWGSOP2, the Asian and international working groups, and the US FNIH project draw different cut-offs on different measures, and prevalence in the same population can shift several-fold depending on which is applied. Trials recruited under one definition cannot be cleanly compared with trials recruited under another, and a regulator asked to approve a sarcopenia drug has no consensus endpoint to approve it against. The 2024 GLIS consensus settled the concept — muscle mass plus strength, with function relegated to an outcome — but deliberately deferred the operational cut-offs, so the harmonisation the pipeline needs is still pending.¹⁰

Beneath the definitional problem sits a biological one: whether sarcopenia is a disease to be treated or simply aging seen in one tissue. The Geroscience hypothesis reads it as the latter — one output of shared hallmark processes, unlikely to yield to a muscle-only intervention any more than Immunosenescence has yielded to an immune-only one. The counterargument is practical: whatever its ultimate cause, sarcopenia has cheap validated endpoints, a code, and an intervention that works, which makes muscle the arena where a compressed morbidity is easiest to demonstrate. The uncomfortable fact for the field is that the comparator any future drug must beat is resistance training — an intervention with effect sizes no molecule has matched, available now, and taken up by only a minority of the people whose remaining Healthspan most depends on it.

§See also

• Exercise as a geroprotector
• Myostatin inhibition
• Stem cell exhaustion
• Hallmarks of aging
• Aging biomarkers
• Healthspan
• Inflammaging

§References